JP2010523676A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523676A5
JP2010523676A5 JP2010503070A JP2010503070A JP2010523676A5 JP 2010523676 A5 JP2010523676 A5 JP 2010523676A5 JP 2010503070 A JP2010503070 A JP 2010503070A JP 2010503070 A JP2010503070 A JP 2010503070A JP 2010523676 A5 JP2010523676 A5 JP 2010523676A5
Authority
JP
Japan
Prior art keywords
composition
liposome
peptide
hiv
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523676A (ja
Filing date
Publication date
Priority claimed from US11/785,077 external-priority patent/US9402893B2/en
Priority claimed from US11/812,992 external-priority patent/US20080057075A1/en
Application filed filed Critical
Priority claimed from PCT/US2008/004709 external-priority patent/WO2008127651A1/en
Publication of JP2010523676A publication Critical patent/JP2010523676A/ja
Publication of JP2010523676A5 publication Critical patent/JP2010523676A5/ja
Pending legal-status Critical Current

Links

JP2010503070A 2007-04-13 2008-04-11 ヒト免疫不全ウイルスに対する中和抗体を誘導する方法 Pending JP2010523676A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/785,077 US9402893B2 (en) 2005-04-12 2007-04-13 Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
US11/812,992 US20080057075A1 (en) 2005-04-12 2007-06-22 Method of inducing neutralizing antibodies to human immunodeficiency virus
US96041307P 2007-09-28 2007-09-28
PCT/US2008/004709 WO2008127651A1 (en) 2007-04-13 2008-04-11 Method of inducing neutralizing antibodies to human immunodeficiency virus

Publications (2)

Publication Number Publication Date
JP2010523676A JP2010523676A (ja) 2010-07-15
JP2010523676A5 true JP2010523676A5 (https=) 2010-11-18

Family

ID=39864256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503070A Pending JP2010523676A (ja) 2007-04-13 2008-04-11 ヒト免疫不全ウイルスに対する中和抗体を誘導する方法

Country Status (6)

Country Link
US (2) US8956627B2 (https=)
EP (1) EP2139516A4 (https=)
JP (1) JP2010523676A (https=)
AU (1) AU2008239628B2 (https=)
CA (1) CA2683752A1 (https=)
WO (1) WO2008127651A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868651A4 (en) 2005-04-12 2010-10-06 Univ Duke METHOD FOR INDUCTION OF NEUTRALIZING ANTIBODIES TO THE HIV VIRUS
JP2010523676A (ja) 2007-04-13 2010-07-15 デューク ユニバーシティ ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20110262526A1 (en) * 2008-09-05 2011-10-27 Haynes Barton F Method of inducing an anti-viral immune response
WO2010114628A2 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
WO2011046623A2 (en) * 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
JP2013520498A (ja) * 2010-02-25 2013-06-06 デューク ユニバーシティー 防御的抗hiv−1抗体の産生を誘導する方法
US20150359874A1 (en) * 2012-03-05 2015-12-17 Duke University Vaccine formulation
WO2015048635A1 (en) * 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US4994440A (en) 1989-02-13 1991-02-19 Creaven Patrick J Method for the treatment of renal cell carcinoma
DE69311764T2 (de) 1992-05-14 1998-02-05 Polymun Scient Immunbio Forsch Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
CA2157900A1 (en) 1993-03-11 1994-09-15 Angeline Douvas Therapeutic strategies for immunoinfective cluster virus infections
ES2204919T3 (es) 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
EP0815852A1 (en) 1993-08-06 1998-01-07 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
DE69426725T2 (de) 1993-09-11 2001-09-06 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren
CA2185129A1 (en) 1994-03-14 1995-09-21 Angeline Douvas Methods to diagnose and treat hiv-1 infection
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU2308595A (en) * 1995-04-19 1996-11-07 Polymun Scientific Immunobiologische Forschung Gmbh Monoclonal antibodies against hiv-1 and vaccines made thereo f
AU5978596A (en) * 1995-06-07 1996-12-30 U.S. Department Of The Army Liposomes containing human immunodeficiency virus glycoprote in and methods for use thereof
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US5901306A (en) * 1997-06-23 1999-05-04 Sun Microsystems, Inc. Method and apparatus for reducing a computational result to the range boundaries of a signed 8-bit integer in case of overflow
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
ES2274100T3 (es) 2001-09-07 2007-05-16 Polymun Scientific Immunbiologische Forschung Gmbh Anticuerpos que reconocen a un peptido que imita a un epitopo criptico de gp41 del vih-1.
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
WO2003059953A2 (en) 2002-01-17 2003-07-24 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7611704B2 (en) 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US7384909B2 (en) 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7790159B2 (en) 2002-07-15 2010-09-07 Board Of Regents, The University Of Texas System Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids
US7906115B2 (en) 2002-07-15 2011-03-15 Thorpe Philip E Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US20040131622A1 (en) 2002-07-15 2004-07-08 Board Of Regents Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
JP2007524603A (ja) 2003-03-27 2007-08-30 ザ ユニバーシティー オブ テキサス Hiv/エイズの受動免疫治療用ループス抗体
US8147840B2 (en) 2004-05-14 2012-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
EP1868651A4 (en) 2005-04-12 2010-10-06 Univ Duke METHOD FOR INDUCTION OF NEUTRALIZING ANTIBODIES TO THE HIV VIRUS
US20080057075A1 (en) 2005-04-12 2008-03-06 Haynes Barton F Method of inducing neutralizing antibodies to human immunodeficiency virus
JP2010523676A (ja) 2007-04-13 2010-07-15 デューク ユニバーシティ ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
JP5331105B2 (ja) 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
US20120070488A1 (en) 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2010114628A2 (en) 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
CA2757306A1 (en) 2009-04-03 2010-10-07 Duke University Formulation

Similar Documents

Publication Publication Date Title
JP2010523676A5 (https=)
RU2375374C2 (ru) Домены и эпитопы менингококкового белка nmb1870
US5352576A (en) Method of determining the presence and titers of anti HIV-1 ag27bodies
JP2018502885A5 (https=)
Pitisuttithum et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
DE60329106D1 (de) Ghrelin-träger-konjugate
JP2007505033A5 (https=)
PE20071055A1 (es) Anticuerpos anti mn
CN1505528A (zh) 包含结合hiv包膜蛋白的配体的免疫原
Fries et al. HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
JP2013505201A5 (https=)
NZ597458A (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
King et al. Achieving cross-reactivity with pan-ebolavirus antibodies
JP2013523783A5 (https=)
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
JP2010523676A (ja) ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
Agrawal et al. Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
Sjölander et al. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-ISCOM preparations. A comparison with other adjuvant systems
NZ515356A (en) Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5
MX2011007745A (es) Division de gp41.
ATE343592T1 (de) Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper
Iglesias et al. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg